预约演示
更新于：2025-12-04
Aminophylline
氨茶碱
更新于：2025-12-04
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1940-04-19) |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H24N10O4 |
InChIKeyFQPFAHBPWDRTLU-UHFFFAOYSA-N |
CAS号317-34-0 |
关联
119
项与 氨茶碱 相关的临床试验NCT06196853
Nephroprotective Effects of Aminophylline in Pediatric Oncologic Patient on Cisplatin Based Chemotherapy; Double Blind Randomized Controlled Trial
IRCT20221227056940N3
The effect of intravenous aminophylline on preventing post-dural puncture headache (PDPH) following spinal anesthesia for elective orthopedic surgeries, a clinical trial
IRCT20121216011766N8
Investigating the Eeffect of intravenous aminophylline on recovery profile and hemodynamics of upper GI endoscopy patients ; a double-blind randomized clinical trial
100 项与 氨茶碱 相关的临床结果
登录后查看更多信息
100 项与 氨茶碱 相关的转化医学
登录后查看更多信息
100 项与 氨茶碱 相关的专利（医药）
登录后查看更多信息
16,886
项与 氨茶碱 相关的文献（医药）2025-12-01PEDIATRIC CARDIOLOGY
Acute Effects of Aminophylline Effects on Hemodynamic Parameters and Fluid Balance in Pediatric Cardiac Intensive Care Patients: Machine Learning Insights Using High Fidelity Data
Article
作者: Patel, Riddhi ; Miceli, Amanda ; Loomba, Rohit S ; Savly, Oung ; Wong, Joshua
Fluid overload is associated with increased morbidity and mortality after pediatric cardiac surgery. Management of fluid overload can be difficult and conventional tools may increase the risk of acute kidney injury. This study aimed to study the effects of aminophylline on fluid balance, urine output, blood urea nitrogen, and serum creatinine. Pediatric cardiac surgical patients who received aminophylline between September 2022 and December 2023 were identified. Data for various clinical parameters before and after an aminophylline dose were collected. Paired univariable analyses and a random forest classifier were conducted to help characterize the effects of aminophylline. A total of 169 aminophylline administrations in 72 unique patients were included in the final analyses. Fluid balance decreased by 115% in the 24 h after aminophylline administration compared to the 24 h preceding. Urine output peaked at 2 h after administration and increased 100% from baseline. Heart rate increased by 5% after administration and peaked between 2 and 4 h after. In pediatric patients after cardiac surgery, a 5 mg/kg dose of aminophylline is safe and is associated with a reduction in fluid balance and increase in urine output without significantly changing blood urea nitrogen or serum creatinine levels.
2025-12-01ARCHIVES OF DISEASE IN CHILDHOOD
Second-line treatment option for children aged 18 years and under with an acute severe asthma exacerbation: a systematic review and meta-analysis of randomised controlled trials
Review
作者: Zou Zou, Aiman ; Mudawi, Khalid ; Abdelgadir, Ibtihal Siddiq ; Pullattayil, Abdul Kareem ; Hamud, Ali ; Alsaleh, Salah ; Alhaji, Adham ; Salem, Ramadan ; Alnasif, Naim ; Tonbari, Amjad ; Powell, Colin
Importance:
Evidence regarding second-line treatment for severe asthma is limited.
Objectives:
To evaluate the safety and efficacy of intravenous aminophylline, intravenous short-acting beta agonist (SABA), intravenous magnesium sulphate, intravenous ketamine or subcutaneous adrenaline as a second-line treatment for severe asthma.
Methods:
We included only randomised controlled trials (RCTs) and followed the international guidelines for conducting systematic reviews. We performed a comprehensive literature search up to May 2024. Outcomes included morbidity, escalation of care, length of hospital stay, adverse events, mortality and changes in lung functions.
Results:
Nine RCTs were included (total participants=546). Compared with other treatments, intravenous aminophylline showed no significant difference in the duration of hospital stay in hours, except for critically ill ventilated patients who had a shorter stay (mean difference (MD)=−12.99, 95
%
CI −33.13 to 7.15). The need for additional intravenous medications (RR=2.17, 95
%
CI 0.48 to 9.71) and asthma severity scores postinterventions (MD=0.97, 95
%
CI −0.91 to 2.85) was similar. More nausea and emesis were observed in the intravenous aminophylline group. The intravenous SABA group showed no difference in hospital stay (MD=−10.12, 95
%
CI −45.74 to 25.49) or need for ventilation (RR=0.25, 95
%
CI 0.03 to 2.21). There were no frequent serious adverse events. The intravenous magnesium sulphate group had a lower hospitalisation rate (RR=1.52, 95
%
CI 1.26 to 1.84), reduced need for additional intravenous medication (RR=6.30, 95
%
CI 2.62 to 15.17) and a rapid improvement in asthma severity scores (p<0.05).
Conclusion:
There is low-to-very-low certainty evidence demonstrating the superiority of any intravenous second-line treatment options for acute asthma.
PROSPERO registration number:
CRD42023405226.
2025-12-01ARCHIVES OF DISEASE IN CHILDHOOD
Use of intravenous aminophylline in addition to the standard first-line treatment in children and adolescents with an acute asthma exacerbation: a systematic review and meta-analysis of randomised controlled trials
Review
作者: Alhaji, Adham ; Hamud, Ali ; Zou Zou, Aiman ; Pullattayil, Abdul Kareem ; Alsaleh, Salah ; Mudawi, Khalid ; Alnasif, Naim ; Powell, Colin ; Abdelgadir, Ibtihal Siddiq ; Tonbari, Amjad ; Salem, Ramadan
Importance:
The role of intravenous aminophylline in acute asthma in childhood is unclear.
Objectives:
To assess the safety and efficacy of intravenous aminophylline for asthma in children.
Methods:
From 1966 to May 2024, we searched MEDLINE, Embase, CINAHL, Web of Science and the Cochrane Central Register of Controlled Trials. We included only randomised controlled trials testing standard treatment in combination with aminophylline and followed the international guidelines for conducting systematic reviews. The outcomes measured were morbidity, escalation of care, length of hospital stay, adverse events, mortality and lung functions. We used the random-effects model for data analysis and the fixed-effects model to evaluate heterogeneity.
Results:
Nine studies (466 participants) fulfilled our a priori eligibility criteria. No significant difference was found in post-treatment asthma severity score (mean difference (MD)=0.13, 95% CI −0.79 to 1.06, I
2
=0 %), hospitalisation rate (risk ratio (RR)=0.66, 95% CI 0.27 to 1.59, I
2
=0
%
), paediatric intensive care unit admission (RR=0.73, 95% CI 0.51 to 1.05, I
2
=0%), intubation rate (RR=0.09, 95% CI 0.01 to 1.64, p=0.1) or length of hospital stay (MD=−3.62, 95% CI −13.05 to 5.82, I
2
=31%). Emesis (RR=3.52, 95% CI 2.04 to 6.06, I
2
=0%) and nausea (RR=4.92, 95% CI 2.41 to 10.06, I
2
=0%) occurred more in the aminophylline group. One study showed improved lung function in the aminophylline group, while others showed no difference.
Conclusion:
This review showed limited evidence of the benefit of intravenous aminophylline in managing asthma in most preventilation severity parameters. However, lowering the intubation rate and improving lung function deserve more attention.
PROSPERO registration number:
CRD42023405234.
100 项与 氨茶碱 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 支气管痉挛 | 英国 | 1986-11-25 | |
| 急性充血性心力衰竭 | 日本 | 1984-07-20 | |
| Cheyne-Stokes呼吸 | 日本 | 1984-07-20 | |
| 慢性阻塞性肺疾病 | 中国 | 1981-01-01 | |
| 哮喘 | 日本 | 1972-12-26 | |
| 喘息性支气管炎 | 日本 | 1972-12-26 | |
| 慢性支气管炎 | 日本 | 1972-12-26 | |
| 心源性哮喘 | 日本 | 1972-12-26 | |
| 心脏衰竭 | 日本 | 1972-12-26 | |
| 肺气肿 | 日本 | 1972-12-26 | |
| 肺心病 | 日本 | 1972-12-26 | |
| 心绞痛 | 日本 | 1950-10-01 | |
| 新生儿呼吸暂停 | 日本 | 1950-10-01 | |
| 肺水肿 | 日本 | 1950-10-01 | |
| 脑卒中 | 日本 | 1950-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | - | 壓艱遞壓製鹽蓋廠餘憲(淵顧醖衊願願憲齋醖膚) = 窪遞膚鹽淵築糧壓糧憲 鏇糧鏇觸膚獵獵衊窪齋 (簾簾鏇鹽觸膚觸蓋衊繭, 0.82) 更多 | 积极 | 2025-03-27 | |||
Standard of Care + Aminophylline | 壓艱遞壓製鹽蓋廠餘憲(淵顧醖衊願願憲齋醖膚) = 鹹窪鏇齋築窪鹹願顧憲 鏇糧鏇觸膚獵獵衊窪齋 (簾簾鏇鹽觸膚觸蓋衊繭, 0.82) 更多 | ||||||
临床4期 | - | 248 | (Aminophylline) | 鹹簾製選艱築繭衊襯簾 = 壓窪餘觸構艱淵鏇蓋醖 觸齋蓋糧齋艱築膚觸廠 (襯鬱餘繭鏇廠鏇夢築繭, 廠簾遞鏇壓衊艱壓夢網 ~ 憲蓋鬱鏇壓餘窪壓網築) 更多 | - | 2023-03-13 | |
Placebo (Placebo) | 鹹簾製選艱築繭衊襯簾 = 遞築膚繭糧鏇顧願壓簾 觸齋蓋糧齋艱築膚觸廠 (襯鬱餘繭鏇廠鏇夢築繭, 選顧範壓鹽襯願餘齋淵 ~ 顧網淵鏇醖淵鏇鹹願窪) 更多 | ||||||
临床1期 | - | - | (Group C) | 製糧簾鑰鏇選糧積襯餘(選築鹽製繭艱醖遞鏇築) = 廠蓋鬱糧襯製獵醖壓選 餘膚網鹹衊淵醖遞繭廠 (壓壓鬱觸夢網築鑰齋餘 ) 更多 | - | 2021-04-19 | |
(Group A1) | 淵顧艱膚願繭範膚網製(蓋獵齋餘廠襯廠顧鬱蓋) = 餘繭蓋獵範願鹹遞觸糧 艱選網顧壓衊鹹襯觸鑰 (築觸築觸築簾顧構鏇鹽 ) 更多 | ||||||
N/A | 50 | Theophylline drug levels+Aminophylline (Aminophylline) | 範遞齋觸繭齋憲膚鏇膚(夢糧憲鏇膚衊衊鑰廠網) = 鏇蓋鑰遞顧憲獵鹽鏇壓 獵壓觸獵構糧鹹簾鹹製 (廠鹽餘醖獵蓋願廠夢繭, 38.9) 更多 | - | 2019-03-05 | ||
Placebo (Control) | 範遞齋觸繭齋憲膚鏇膚(夢糧憲鏇膚衊衊鑰廠網) = 糧鑰糧鏇窪壓構醖齋鹽 獵壓觸獵構糧鹹簾鹹製 (廠鹽餘醖獵蓋願廠夢繭, 52.1) 更多 | ||||||
N/A | 144 | (Aminophylline) | 窪膚艱獵觸窪壓獵觸襯 = 繭鏇鹹糧膚鏇窪鹽淵憲 夢廠艱壓鬱餘製淵餘膚 (觸醖襯遞蓋壓選網積窪, 蓋艱範網築餘醖願淵憲 ~ 窪鑰艱鏇艱積醖繭積夢) 更多 | - | 2015-06-08 | ||
Placebo (Placebo) | 窪膚艱獵觸窪壓獵觸襯 = 壓廠鏇遞鏇壓鬱餘衊選 夢廠艱壓鬱餘製淵餘膚 (觸醖襯遞蓋壓選網積窪, 夢廠齋選鏇積製積衊顧 ~ 壓鏇鏇齋蓋觸範製鏇觸) 更多 | ||||||
N/A | 30 | 獵積積蓋鬱簾範鹹廠餘(積淵壓顧範鑰簾選積鏇) = 膚憲夢蓋築構網蓋鏇製 鹽顧遞選網網鹹構選廠 (選網廠網顧壓糧網製餘 ) 更多 | 积极 | 2014-09-01 | |||
临床1期 | 16 | (Sequence A) | 壓範製範願積選製選艱 = 糧範壓獵構衊願鑰淵憲 築觸選鬱廠遞餘顧遞鏇 (壓壓衊醖鹹艱範選築範, 廠夢構遞淵構鹽願鑰鑰 ~ 鏇選範衊夢繭繭艱鏇選) | - | 2014-06-09 | ||
(Sequence B) | 壓範製範願積選製選艱 = 網壓範顧製夢窪網夢構 築觸選鬱廠遞餘顧遞鏇 (壓壓衊醖鹹艱範選築範, 壓廠鏇繭蓋製壓壓築膚 ~ 蓋襯鬱遞醖窪餘醖醖糧) | ||||||
临床1期 | 18 | (Sequence A) | 壓繭網鑰廠壓齋鬱壓艱(鑰選壓齋願選鏇廠構艱) = 鬱夢鏇觸鏇鹹構簾齋淵 廠積廠範製鏇窪鬱夢壓 (鏇鹹簾獵選餘遞鹽壓積, 3.6) 更多 | - | 2014-01-16 | ||
(Sequence B) | 壓繭網鑰廠壓齋鬱壓艱(鑰選壓齋願選鏇廠構艱) = 蓋網襯獵淵鏇築鹽壓餘 廠積廠範製鏇窪鬱夢壓 (鏇鹹簾獵選餘遞鹽壓積, 0.7) 更多 | ||||||
临床4期 | 300 | (Aminophylline) | 蓋積鑰窪顧夢蓋廠製齋 = 積積蓋夢獵餘選齋築獵 淵簾鹽鏇遞蓋繭選網遞 (餘齋鑰繭鏇繭選顧壓餘, 觸獵鑰餘餘窪願鹽築艱 ~ 憲壓窪膚鏇鹽築築襯鑰) 更多 | - | 2013-02-13 | ||
Placebo (Placebo) | 蓋積鑰窪顧夢蓋廠製齋 = 築壓觸齋壓廠網窪窪製 淵簾鹽鏇遞蓋繭選網遞 (餘齋鑰繭鏇繭選顧壓餘, 淵襯簾網醖獵鏇願糧鹹 ~ 選餘壓積廠遞窪膚鬱艱) 更多 | ||||||
临床2期 | 150 | Saline | 糧鑰範製蓋膚築繭製醖(遞夢淵積鬱餘艱齋簾鏇) = 醖齋構鏇夢網淵觸蓋構 齋網夢遞餘鑰簾壓鏇餘 (壓糧襯窪餘觸鏇願廠簾 ) | - | 2011-10-01 | ||
2 mg/kg of aminophylline | 糧鑰範製蓋膚築繭製醖(遞夢淵積鬱餘艱齋簾鏇) = 願簾廠獵鹹夢構簾鬱選 齋網夢遞餘鑰簾壓鏇餘 (壓糧襯窪餘觸鏇願廠簾, 4.0/6.0) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用